Vonoprazan Improves Efficacy of Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter Randomized Controlled Trial
- 13 July 2025
- journal article
- research article
- Published by Wiley in Helicobacter
- Vol. 30 (4) , e70056
Abstract
Background: Rescue treatment for non‐naive patients with persistent Helicobacter pylori (H. pylori) infection is lacking, especially in areas where tetracycline is unavailable. This trial aimed to evaluate the efficacy and safety of replacing proton pump inhibitor (PPI) with potassium‐competitive acid blocker (P‐CAB) in bismuth quadruple therapy (BQT) containing amoxicillin and furazolidone as rescue therapy.Materials and Methods: We conducted a prospective, open‐label, noninferiority randomized controlled trial at six institutions in eastern China. A total of 444 patients with a history of H. pylori treatment failure were enrolled and randomly assigned in a 1:1 ratio to either the 14‐day P‐CAB‐BQT group (vonoprazan 20 mg, colloidal bismuth 200 mg, amoxicillin 1000 mg and furazolidone 100 mg, all given twice daily) or the 14‐day PPI‐BQT group (rabeprazole 10 mg given twice daily, and the same dose of three other drugs as the 14‐day P‐CAB‐BQT group). The primary endpoint was the eradication rate assessed by 13C urea breath test. The secondary endpoints were adverse events and compliance.Results: H. pylori eradication rates of PPI‐BQT versus P‐CAB‐BQT group were 83.8% versus 91.9% in the intention‐to‐treat (ITT) analysis (treatment difference: 8.1%; 95% CI: 2.1%–14.1%; non‐inferiority p < 0.001, p‐value for difference = 0.008); 86.1% versus 95.8% in the modified ITT (MITT) analysis (treatment difference: 9.7%; 95% CI: 4.4%–15.0%; non‐inferiority p < 0.001, p‐value for difference < 0.001); and 86.3% versus 95.6% in the per‐protocol (PP) analysis (treatment difference: 9.3%; 95% CI: 3.8%–14.8%; non‐inferiority p < 0.001, p‐value for difference < 0.001). The P‐CAB‐BQT regimen was shown to be non‐inferior to the PPI‐BQT regimen and yielded higher eradication rates across all analysis populations (ITT, MITT, and PP). The overall frequency of adverse events (27.9% and 34.2%, p = 0.151) and compliance (93.7% and 94.6%, p = 0.686) were similar between PPI and P‐CAB groups. Among the patients suspected of drug‐induced fever (8.6% and 7.2%, p = 0.597), 82.9% experienced fever after administration of furazolidone for > 10 days. The eradication rates were not affected by prior choice of antibiotics and the number of treatment attempts.Conclusions: The 14‐day P‐CAB‐BQT therapy containing amoxicillin and furazolidone provided a satisfactory eradication rate and a good safety profile as rescue treatment for H. pylori eradication, regardless of prior choice of antibiotics and the number of treatment attempts. Shortening the treatment course to 10–11 days could prevent the majority of drug‐induced fevers.Keywords
Funding Information
- National Natural Science Foundation of China (81600447, 81970498)
- Natural Science Foundation of Zhejiang Province (LZ22H030002)
- Medical and Health Research Project of Zhejiang Province (2024XY170)
This publication has 37 references indexed in Scilit:
- Vonoprazan improves the efficacy of bismuth quadruple therapy containing doxycycline and metronidazole as first-line Helicobacter pylori treatment in penicillin-allergic patients: a randomized controlled trialJournal of Antimicrobial Chemotherapy, 2025
- Efficacy and safety of tetracycline vs. amoxicillin in furazolidone-based rescue therapy for Helicobacter pylori : a real-world analysisAnnals of Medicine, 2025
- Antibiotic resistance of Helicobacter pylori in Mainland China: A focus on geographic differences through systematic review and meta-analysisInternational Journal of Antimicrobial Agents, 2024
- 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatmentChinese Medical Journal, 2022
- Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical TrialGastroenterology, 2022
- Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple TherapyAmerican Journal of Gastroenterology, 2016
- Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trialThe Lancet, 2011
- Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypesEuropean Journal of Clinical Pharmacology, 2006
- Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statisticsStatistics in Medicine, 2002
- Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazoleAlimentary Pharmacology & Therapeutics, 1999